Mechanism of action
hemoglobin S polymerization inhibitor
Diseases for which it is used
History of changes in FDA indication
- 11/25/2019: Granted accelerated approval for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.
Also known as
- Code names: GBT-440, GTx-011
- Brand name: Oxbryta